new molecules and indications for glp-1 medicines Emerging Color coding GLP-1 receptor agonists and next-generation

Yes, patients with type 2 diabetes should be monitored for hypoglycaemia, especially if taking insulin or sulfonylureas alongside Wegovy

Additionally, we are grateful for the collaboration of the avexitide clinical trial investigators. Post-bariatric hypoglycemia places a tremendous burden on individuals, with frequent and unpredictable hypoglycemic events that can cause severe symptoms such as impaired cognition, loss of consciousness, and seizures, said Endocrine Society member Marilyn Tan, MD , principal investigator of the LUCIDITY clinical trial and clinical associate professor of medicine at Stanford University School of Medicine

anti-obesity)

Key highlights Tirzepatide is the first dual GLP-1/GIP receptor agonist that offers stronger appetite suppression, improved glycemic control, and provides significantly greater weight loss than single receptor agonists such as semaglutide, liraglutide, and dulaglutide

Now then the Next Generation, the second one, approved in 2021, that includes Ozempic, of course, the trade name for the treatment of diabetes and Wegovy, the trade name for the treatment of obesity